Date: 2015-10-20
Type of information: Collaboration agreement
Compound: lncRNAs
Company: RXi Pharmaceuticals (USA - MA) Biogazelle (Belgium)
Therapeutic area:
Type agreement: collaboration
Action mechanism: lncRNAs are a diverse class of non-protein coding RNA molecules that are greater than 200 nucleotides in length. lncRNAs are involved in crucial cellular processes, including the regulation of gene expression, and have been implicated in many diseases and disorders, including cancer, cardiovascular diseases, neurological disorders, diabetes, and HIV.
Disease:
Details: * On October 20, 2015, RXi Pharmaceuticals, a biotechnology company focused on discovering and developing innovative therapies primarily in the areas of dermatology and ophthalmology, announced positive results from a collaboration with Biogazelle NV. Biogazelle is a company with a longstanding track record and internationally recognized expertise in RNA gene expression analysis, with a particular focus on non-coding RNA, such as microRNAs and long non-coding RNAs (lncRNA). Specifically-designed sd-rxRNAs based on RXi\'s proprietary, self-delivering RNAi platform demonstrated robust and potent reduction of the levels of lncRNAs in a target specific manner. These findings expand the number of potential genes RXi is capable of targeting by approximately four fold.
Financial terms:
Latest news:
